(Corrects headline and first paragraph to “prostate” from “prostrate”)
Sept 14 (Reuters) - Pfizer Inc and Astellas Pharma Inc said on Thursday their drug to treat a type of prostate cancer met the main goal of improving overall survival in a late-stage trial.
The oral drug, Xtandi, in combination with an anti-hormone therapy was more successful than an anti-hormone therapy alone in improving overall survival in men with non-metastatic castration-resistant prostate cancer.
The drug is already approved to treat metastatic castration-resistant prostate cancer. (Reporting by Tamara Mathias in Bengaluru; Editing by Savio D‘Souza)